Format

Send to

Choose Destination
Methods Mol Biol. 2018;1693:159-170. doi: 10.1007/978-1-4939-7395-8_14.

Compassionate Use of Bacteriophage Therapy for Foot Ulcer Treatment as an Effective Step for Moving Toward Clinical Trials.

Author information

1
PhageBiotics Research Foundation, Gray's Harbor Community Hospital, Aberdeen, WA, USA. rcfish4@gmail.com.
2
Wound Centers at St Joseph's Medical Center, Tacoma, WA, USA. rcfish4@gmail.com.
3
PhageBiotics Research Foundation, Gray's Harbor Community Hospital, Aberdeen, WA, USA.
4
Bacteriophage Lab - The Evergreen State College, Evergreen Parkway NW, Olympia, WA, 98505, USA.
5
Kaiser Permanente Northwest, Saint Peter Hospital Family Medicine Residency, 3324 Sunset Beach Dr., Olympia, WA, 98502, USA.
6
Laboratory of Gene Technology, KU Leuven, Kasteelpark Arenberg, 21, Belgium.
7
George Eliava Institute of Bacteriophages, Microbiology and Virology - 3, Gotua str., Tbilisi, 0160, GA, USA.
8
VA Northern California, Muir Road, Martinez, CA, 94553, USA.
9
University of California, San Francisco, CA, USA.

Abstract

We here present detailed descriptions of successful treatment of a series of diabetic toe ulcers using the Eliava BioPreparations' commercial preparation of the very well-studied anti-staphylococcal bacteriophage Sb-1. This chapter outlines what we feel is an appropriate mechanism to speed movement toward full-scale clinical trials with bacteriophage use to treat wound infections and to help address the crisis in antibiotic resistance.

KEYWORDS:

Amputation; Bacteriophage therapy; Debridement; Diabetic foot ulcers; Osteomyelitis

PMID:
29119440
DOI:
10.1007/978-1-4939-7395-8_14
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center